MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Second Sight Medical Products EBITDA 2011-2026 | EYES
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Second Sight Medical Products
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.3 M | -26.6 M | -20.9 M | -13 M | -12.5 M | -30.2 M | -34.2 M | -28.2 M | -32.8 M | -19.7 M | -21 M | -17.7 M | -15.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.5 M | -34.2 M | -22.8 M |
Quarterly EBITDA Second Sight Medical Products
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.62 M | -7.36 M | -6.46 M | - | -6.2 M | -5.58 M | -6.13 M | - | - | - | -6.49 M | - | -5.17 M | -4.06 M | -3.82 M | -1.29 M | -3.22 M | -2.26 M | -2.82 M | -1.27 M | -1.45 M | -2.99 M | -8.8 M | -8.13 M | -7.33 M | -8.24 M | -9.67 M | -8.88 M | -8.22 M | -7.77 M | -9.66 M | -7.43 M | -6.4 M | -6.64 M | -7.44 M | -10.4 M | -8.19 M | -8.3 M | -5.72 M | -5.48 M | -4.43 M | -4.79 M | -4.96 M | -5.56 M | -5.44 M | -5.42 M | -4.38 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.27 M | -10.4 M | -5.97 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-9 M | $ 2.22 | 5.21 % | $ 3.47 M |  USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 10.45 | 0.29 % | $ 1.41 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.36 | -0.24 % | $ 600 M |  Israel |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 13.05 | 3.57 % | $ 1.96 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 4.27 | 9.21 % | $ 904 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 71.2 | 2.02 % | $ 105 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.06 | 2.53 % | $ 151 M |  France |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 37.34 | -0.16 % | $ 1.16 B | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.68 | 4.61 % | $ 37 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.16 | 1.18 % | $ 302 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 65.01 | 2.41 % | $ 1.93 B |  Costa-rica |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.45 | 0.16 % | $ 121 M | USA |
 |
InMode Ltd.
INMD
|
86.1 M | $ 13.65 | 1.64 % | $ 882 M | Israel |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
9.49 B | $ 110.71 | 0.69 % | $ 193 B | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 9.74 | -0.71 % | $ 349 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.6 | 0.39 % | $ 153 M | Israel |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 269.48 | 3.15 % | $ 7.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.17 | -0.91 % | $ 1.32 M | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 32.75 | -0.27 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
753 M | $ 176.12 | 3.94 % | $ 13.2 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.1 | 1.0 % | $ 701 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 33.74 | 2.99 % | $ 5.03 K | USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 3.74 | 1.91 % | $ 154 M | USA |
 |
Accuray Incorporated
ARAY
|
14 M | $ 0.39 | -6.07 % | $ 40.1 M | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.33 | - | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
27.3 M | $ 102.8 | 1.09 % | $ 1.31 B | USA |